CHU

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Retrieved on: 
Tuesday, September 26, 2023
Rett, Index, FRCP, Central nervous system, Pediatrics, Health care, IDMC, MECP2, Rett syndrome, Neuroscience, AAV, CNS, Associate, CHU, FAAP, Clinical trial, Investigational New Drug, Patient, Child, MAD, MTD, Principal, FDA, Safety, IND, MHRA, Pharmaceutical industry

DALLAS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the second Rett syndrome patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial in Canada.

Key Points: 
  • DALLAS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the second Rett syndrome patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial in Canada.
  • “Dosing the second adult patient in the REVEAL Phase 1/2 adult trial in Canada marks important progress in the ongoing clinical evaluation of TSHA-102 for Rett syndrome,” said Sukumar Nagendran, M.D., President, and Head of R&D of Taysha.
  • The maximum tolerated dose (MTD) or maximum administered dose (MAD) established will then be administered during dose expansion.
  • Enrollment in the low-dose cohort is expected to be complete in the fourth quarter of 2023 with the dosing of the third patient.

IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress

Retrieved on: 
Friday, September 8, 2023
ENT, Endometriosis, CE, Abstract, IR, Plantar fibromatosis, Travel, Ablation, Cryoablation, Q&A, Neoplasm, Woman, Breast, CIRSE, Doctor of Philosophy, Lung, Congress, CHU, Traction, Freezing, Circulatory system, Cardiovascular and Interventional Radiological Society of Europe, Kidney, Liver, Malignancy, LN2, Medical imaging, Management, MD

IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.

Key Points: 
  • IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.
  • IceCure will be participating in the Tumor Ablation Hands-On Device Training with the ProSense cryoablation system.
  • This is a great opportunity for attendees to gain hands-on knowledge of IceCure's cryoablation device and to see the system's advantages.
  • Thanks to this grant, ten aspiring women interventional radiologists' abstracts were accepted and will receive sponsored congress registration, travel, and accommodation.

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

Retrieved on: 
Thursday, July 13, 2023
Mental Health, Research, Seniors, Neurology, Biotechnology, Health, Consumer, Pharmaceutical, Science, Faculty, Patent, Central nervous system, Depression, PD, Université Laval, Anxiety, Leslie Dan Faculty of Pharmacy, NMDAR, CNS, CHU, MPTP, Cell, Parkinson's disease, Patient, CIPO, Canadian Intellectual Property Office, Dyskinesia, L-DOPA, LID, Pharmaceutical industry, Pharmacy

AV-101 is the Company’s oral prodrug antagonist at the NMDAR (N-methyl-D-aspartate receptor) glycine site.

Key Points: 
  • AV-101 is the Company’s oral prodrug antagonist at the NMDAR (N-methyl-D-aspartate receptor) glycine site.
  • The patent, once granted, will not expire until at least 2034.
  • The U.S. Patent and Trademark Office (USPTO) granted a related U.S. patent for Vistagen’s AV-101 and similar patents have been granted or are pending in several additional major pharmaceutical markets.
  • The study demonstrated that AV-101 significantly (p = 0.01) reduced LID without affecting the timing, extent, or duration of the therapeutic benefits of L-Dopa.

Pure Storage Enables Leading French University Hospital to Accelerate Critical Healthcare Data, Modernize Storage Infrastructure to Improve Patient Care

Retrieved on: 
Tuesday, July 11, 2023
Maintenance, Pediatrics, Teaching, Ageing, Research, Teaching hospital, CHU, University Hospital Centre Zagreb, PSTG, Patient, University Hospital (Newark, New Jersey), Pure Storage, Operations management, Pure, Health, Environment, NYSE, Country, Nursing, Transport, Dairy, Computer data storage

Faced with growing demands and limited space, the hospital needed to modernize its IT infrastructure, which serves as the foundation for all of its patient systems.

Key Points: 
  • Faced with growing demands and limited space, the hospital needed to modernize its IT infrastructure, which serves as the foundation for all of its patient systems.
  • Pure Storage provides CHU Saint-Etienne the availability, security, and performance it needs to both scale and improve patient care, while enabling easy maintenance for its small IT team.
  • Benefits include:
    Modernized, Efficient Storage Infrastructure: With Pure Storage FlashArray, CHU Saint-Etienne has significantly reduced its power consumption while increasing storage capacity by 50% compared to its legacy storage environment.
  • "Moving our legacy storage environment to Pure Storage was one of the best decisions we could have made as an IT team.

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Retrieved on: 
Wednesday, June 28, 2023
Logarithm, Central nervous system, Natural history, Probability, Neurodegenerative disease, IDMC, Food and Drug Administration, Skin, MECP2, Rett syndrome, CTA, SNAP, AAV, CNS, Compound muscle action potential, U.S. FDA, CHU, Regeneration, Data analysis, Visual acuity, GAN, DPM, HIV disease progression rates, Patient, CMAP, Child, FDA, UK, IND, LogMAR chart, Food, Safety, Disease, Peripheral nervous system, Pharmaceutical industry, Medical imaging, DALLAS, List of things named after Thomas Bayes

DALLAS, June 28, 2023 (GLOBE NEWSWIRE) --  Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), announced new data analyses for TSHA-120 in GAN and initial clinical observations for TSHA-102 in Rett syndrome. Taysha will host a virtual R&D Day today at 10:00 AM ET to discuss these updates. The webcast link can be accessed on the Events and Presentations section of Taysha’s website.

Key Points: 
  • Taysha will host a virtual R&D Day today at 10:00 AM ET to discuss these updates.
  • The webcast link can be accessed on the Events and Presentations section of Taysha’s website.
  • We’ve requested a formal FDA meeting to discuss these new developments to support a potential regulatory path forward for TSHA-120.
  • TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) platform designed to regulate cellular MECP2 expression.

Dr. Michele L. Ramien takes the helm as President of the Canadian Dermatology Association

Retrieved on: 
Monday, June 19, 2023
Royal college, University, Physician, Toronto, Pediatric Dermatology, Boston, St George Hospital, Mumbai, University of Ottawa Heart Institute, Certification, CDA, CHU, American Board of Commissioners for Foreign Missions, Royal College of Physicians and Surgeons of Canada, American Board of Dermatology, Hospital, Surgeon, McGill University, Nursing, Dermatology

OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is proud to announce the appointment of Dr. Michele L. Ramien as CDA President, effective June 16, 2023.

Key Points: 
  • OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is proud to announce the appointment of Dr. Michele L. Ramien as CDA President, effective June 16, 2023.
  • Dr. Ramien plans to advocate for, protect, and support the interests of Certified Dermatologists and the specialty of dermatology during her appointment as President.
  • Dr. Ramien brings strategic leadership, clinical expertise, and a growth-oriented mindset to the CDA, and has held previous positions as President Elect and Vice-President of the association.
  • The CDA welcomes Dr. Ramien as President, Canadian Dermatology Association for a one-year term.

Relay Robotics Introduces New Hospital Delivery Robot, RelayRx to Address Nursing Shortage

Retrieved on: 
Monday, June 12, 2023
Technology, Medical Supplies, Hospitals, Other Technology, Health Technology, Other Health, Hardware, General Health, Robotics, Health, American Hospital Association, Workforce, University, Beth Israel Deaconess Medical Center, Pharmacy, Hospital, OTIS, University of California, Multimedia, MedStar Georgetown University Hospital, Mitsubishi Group, TK, CHU, KONE, Patient, Nursing, News Hour, ASHP, El Camino Hospital, Society, PBS, American Society of Health-System Pharmacists, 3D printing, Computer data storage

Relay delivery robots have been deployed at 15+ hospital systems over the past five years.

Key Points: 
  • Relay delivery robots have been deployed at 15+ hospital systems over the past five years.
  • RelayRx delivers twice the capacity (10 gallons, 41 liters) of earlier models, with an expanded 8” touchscreen.
  • View the full release here: https://www.businesswire.com/news/home/20230612385420/en/
    RelayRx High-Capacity Hospital Delivery Robot (Photo: Business Wire)
    This announcement of RelayRx comes at a key economic time in healthcare.
  • This enables RelayRx to navigate throughout an entire hospital, connecting departments like the pharmacy and blood bank with patient rooms with an average delivery time of seven minutes.

Bionano Announces Extensive Lineup of Content at European Conferences Featuring OGM Utility Across a Broad Range of Research Applications

Retrieved on: 
Thursday, June 8, 2023
Immortalised cell line, Cell, MH, Genetics, Acute lymphoblastic leukemia, Ibis, Cancer, Research, DSM-IV codes, CHU, Gene editing, Radbod, UZ Leuven, EHA, European Central Bank, OGM, Bone marrow, Medical device, Online shopping

Scientific posters from Dr. Jose Garcia Martinez (Hospital Infantil Universitario Niño Jesús) and Dr. Jonathan Lühmann (MH Hannover) will cover OGM’s use in pediatric acute lymphoblastic leukemia research.

Key Points: 
  • Scientific posters from Dr. Jose Garcia Martinez (Hospital Infantil Universitario Niño Jesús) and Dr. Jonathan Lühmann (MH Hannover) will cover OGM’s use in pediatric acute lymphoblastic leukemia research.
  • “Researchers and scientists continue to push forward cutting-edge research in the human genetics space, and we are pleased to see them share their findings with conference attendees.
  • These presentations point to the continued expansion of OGM into clinical research applications for cancer, genetic disease and cell therapy where we believe OGM has the potential to deliver significant advantages relative to the current methodologies.”
    For more information on EHA, please visit https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ .
  • For more information on ESHG, please visit https://bionano.com/eshg2023/ .

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Retrieved on: 
Monday, June 5, 2023
Communication, Index, FRCP, Central nervous system, Pediatrics, VG, Clinical trial, MECP2, Rett syndrome, Neuroscience, Gene expression, AAV, CNS, Associate, CHU, FAAP, Patient, Child, MAD, MTD, Principal, Safety, Disease, Pharmaceutical industry, Rett

DALLAS, June 05, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the first patient has been dosed with TSHA-102 in the Phase 1/2 REVEAL trial evaluating the safety and preliminary efficacy of TSHA-102 in adult patients with Rett syndrome. TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy that utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) platform designed to regulate cellular MECP2 expression. The study is being conducted at CHU Sainte-Justine, the Université de Montréal mother and child university hospital centre in Montreal, Canada.

Key Points: 
  • The study is being conducted at CHU Sainte-Justine, the Université de Montréal mother and child university hospital centre in Montreal, Canada.
  • This is a significant milestone that furthers our quest to bring a potentially transformational gene therapy to patients and families living with Rett syndrome.
  • The dosing of the first patient in this important clinical trial represents a critical advancement in evaluating the potential of gene therapy for Rett syndrome.
  • We’re pleased to collaborate with Taysha Gene Therapies in an effort to bring a gene therapy treatment that could meaningfully change the lives of patients and their caregivers.”

Tube China 2023 - International Tube & Pipe Industry Trade Fair will be held at Shanghai New International Expo Centre from 14 to 16 June

Retrieved on: 
Tuesday, April 11, 2023
Communication, China Council for the Promotion of International Trade, Marketing, CITIC, CISRI, MDC, Shanghai New International Expo Center, CHU, Renewable energy, CNE, Conference, Safety, Plastic, Exhibition, Printing, China Metallurgical Group Corporation, FREE, HUAWEI, Letter, Workforce, CISA, Central Iron Ore Enrichment Works, Green, MDS, CHINA, CCPIT, MCC, Health, International trade, Nursing, Video game

SHANGHAI, April 11, 2023 /PRNewswire/ -- Tube China, China's No.1 international trade fair for the tube and pipe industries, will be held at the Shanghai New International Expo Centre from 14 to 16 June 2023, concurrently with METALLURGY CHINA 2023, the leading exhibition of the metallurgical industry.

Key Points: 
  • SHANGHAI, April 11, 2023 /PRNewswire/ -- Tube China, China's No.1 international trade fair for the tube and pipe industries, will be held at the Shanghai New International Expo Centre from 14 to 16 June 2023, concurrently with METALLURGY CHINA 2023, the leading exhibition of the metallurgical industry.
  • During the three show days, Tube China and METALLURGY CHINA 2023 are expected to gather more than 500 key suppliers in the industry.
  • China International Steel Tube & Pipe Industry Summit Forum, The Green & Smart Manufacture Conference of China Steel industry, as well as the Exhibitor Technology Seminar, will be held during the show time.
  • Here at Tube China 2023, you can find the answer to everything you want to know about the tube and pipe industries.